ECLIPSE BIOINNOVATIONS, INC. filed a Form D with the Securities and Exchange Commission on 2025-11-20.
ECLIPSE BIOINNOVATIONS, INC. filed a Form D notice of an exempt securities offering with the SEC on November 20, 2025. The filing reports $4.91M sold. Its industry group is Biotechnology. It names Peter Chu (Executive Officer, Director), Edmond Wong (Director), Daniel Vasella (Director) (SEC Form D, November 20, 2025).
Is this your company?
Sell to companies like ECLIPSE BIOINNOVATIONS, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-11-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ECLIPSE BIOINNOVATIONS, INC.
Free to see. No signup.
More on the people and the money behind ECLIPSE BIOINNOVATIONS, INC., from the filings we hold.
Biotechnology raises by companies based in California, filed in November 2025, largest first.
Get an email when ECLIPSE BIOINNOVATIONS, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ECLIPSE BIOINNOVATIONS, INC. raises, hires or launches. No email unless you switch it on.
Watch ECLIPSE BIOINNOVATIONS, INC. →Get the full cited report on ECLIPSE BIOINNOVATIONS, INC.
What the filing shows about ECLIPSE BIOINNOVATIONS, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ECLIPSE BIOINNOVATIONS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives ECLIPSE BIOINNOVATIONS, INC.'s address as 5770 Oberlin Dr., San Diego, CA 92121.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on ECLIPSE BIOINNOVATIONS, INC. See pricing
ECLIPSE BIOINNOVATIONS, INC. is a registered filer with the SEC (CIK 1881936) and has filed since 2025-11-20. 1 filing is on record, the latest on 2025-11-20.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
ECLIPSE BIOINNOVATIONS, INC.'s Form D of 2025-11-20 names Peter Chu, Edmond Wong, Daniel Vasella and 1 more as its officers, directors or promoters.
Its new offerings report $4.91M sold across 1 offering, as its own filings state.
Trailing twelve months. 764 filings in Biotechnology, totalled by week. The dot is this raise, $4.91M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Peter Chu is named as Executive Officer and Director on the Form D that ECLIPSE BIOINNOVATIONS, INC. filed with the SEC on 20 November 2025, one of 4 people that filing names.
Edmond Wong is named as Director on the Form D that ECLIPSE BIOINNOVATIONS, INC. filed with the SEC on 20 November 2025, one of 4 people that filing names.
Daniel Vasella is named as Director on the Form D that ECLIPSE BIOINNOVATIONS, INC. filed with the SEC on 20 November 2025, one of 4 people that filing names.
Eugene Yeo is named as Director on the Form D that ECLIPSE BIOINNOVATIONS, INC. filed with the SEC on 20 November 2025, one of 4 people that filing names.
4 people named on the filing — 1 holding an executive role and 3 as directors only.
Named as of the 2025-11-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ECLIPSE BIOINNOVATIONS, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ECLIPSE BIOINNOVATIONS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ECLIPSE BIOINNOVATIONS, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ECLIPSE BIOINNOVATIONS, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind ECLIPSE BIOINNOVATIONS, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ECLIPSE BIOINNOVATIONS, INC.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/eclipse-bioinnovations-inc-form-d-25000001